SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics,
Inc. ("Heron") (NASDAQ: HRTX), a commercial-stage biotechnology
company focused on improving the lives of patients by developing
best-in-class treatments to address some of the most important
unmet patient needs, today announced that it intends to offer and
sell shares of its common stock in an underwritten registered
public offering. Heron intends to grant the underwriters of the
offering a 30-day option to purchase up to an additional 15% of the
shares sold in the public offering. All of the shares of common
stock in the offering are to be sold by Heron. The offering
is subject to market conditions, and there can be no assurance as
to whether or when the offering may be completed, or the actual
size or terms of the offering.
Heron intends to use the proceeds from the proposed sale of its
shares of common stock for the commercial launch of HTX-011, if
approved by the U.S. Food and Drug Administration, the continued
commercialization and marketing of SUSTOL® and
CINVANTI®, Heron's ongoing and future clinical trials,
including further clinical studies for HTX-011, preclinical
development work, other product development activities and general
corporate purposes.
Jefferies, Cowen and Evercore ISI are acting as joint
book-running managers for the offering. Cantor is acting as lead
manager for the offering, and JMP Securities, Needham & Company
and Northland Capital Markets are acting as co-managers for the
offering.
The offering is being made pursuant to a registration statement
that was filed with the U.S. Securities and Exchange
Commission (the "SEC") and became automatically effective on
July 6, 2017. A preliminary prospectus supplement and
accompanying base prospectus relating to and describing the terms
of the offering will be filed with the SEC. The securities
described above have not been qualified under any state blue sky
laws. This press release shall not constitute an offer to sell or
the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction. Copies of
the preliminary prospectus supplement and accompanying prospectus
relating to these securities may also be obtained by sending a
request to Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at
(877) 821-7388, or by email at Prospectus_Department@Jefferies.com,
Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY,
11717, Attn: Prospectus Department, by email at
PostSaleManualRequests@broadridge.com or by telephone at (833)
297-2926; or Evercore Group L.L.C. at Attention Equity Capital
Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by telephone at (888)
474-0200, or by email at ecm.prospectus@evercore.com.
Forward-Looking Statements
This news release contains
"forward-looking statements" as defined by the Private Securities
Litigation Reform Act of 1995, including statements regarding
Heron's expectations of the completion and timing of the proposed
public offering. Heron cautions readers that forward-looking
statements are based on management's expectations and assumptions
as of the date of this news release and are subject to certain
risks and uncertainties that could cause actual results to differ
materially, including, but not limited to, those associated with:
risks and uncertainties associated with market conditions and the
satisfaction of customary closing conditions related to the
proposed public offering, its capital position and the sufficiency
of its capital to fund its operations in future periods; its use of
the net proceeds of the proposed public offering; and other risks
and uncertainties identified in its filings with the SEC.
Forward-looking statements reflect its analysis only on their
stated date, and Heron undertakes no obligation to update or revise
these statements except as may be required by law.
Investor Relations Contact:
Heron Therapeutics,
Inc.
David Szekeres, 858-251-4447
Senior Vice President, General Counsel, Business Development &
Corporate Secretary
dszekeres@herontx.com
and
Corporate Contact:
Heron Therapeutics, Inc.
David Szekeres, 858-251-4447
Senior Vice President, General Counsel, Business Development &
Corporate Secretary
dszekeres@herontx.com
View original
content:http://www.prnewswire.com/news-releases/heron-therapeutics-announces-proposed-public-offering-of-common-stock-300930881.html
SOURCE Heron Therapeutics, Inc.